Form 4: Bicycle Therapeutics Director Receives Equity Awards

Bicycle Therapeutics PLC Director Gregory Paul Winter was granted 9,500 restricted share units and 19,000 stock options, vesting throughout 2026.

Summary

• Gregory Paul Winter, a Director of Bicycle Therapeutics PLC, was granted equity awards on January 2, 2026.
• The awards include 9,500 Restricted Share Units (RSUs) and 19,000 stock options.
• Each RSU represents a contingent right to receive one ordinary share, acquired at a price of $0.
• The stock options have an exercise price of $7.08 per share and an expiration date of January 2, 2036.
• Both the RSUs and stock options will vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• Following these transactions, Mr. Winter beneficially owns 196,427 Ordinary Shares and 19,000 Stock Options.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged transaction.

Sentiment

Score: 7

Explanation: The filing indicates routine compensation for a director, which is generally positive for aligning interests but does not suggest significant new developments or financial performance changes. The pre-planned nature (10b5-1) makes it a neutral, expected event.

Positives

• The granting of equity awards to a director aligns management incentives with shareholder interests.
• The awards are part of a pre-planned compensation structure, indicating stability in executive compensation.

Future Outlook

The vesting schedule for the granted RSUs and stock options extends through December 2026, indicating future share issuances and potential exercises based on performance and market conditions.

Industry Context

Equity awards like RSUs and stock options are standard compensation tools in the biotechnology and pharmaceutical industries, particularly for directors and executives, to attract, retain, and incentivize key personnel by aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of RSUs and stock options for director compensation is a common practice across the biotechnology and broader public company landscape, comparable to compensation structures at companies like Moderna, BioNTech, or Regeneron, which frequently utilize equity-based incentives to retain top talent and align interests.
• The vesting schedule over approximately one year is typical for such awards, designed to encourage long-term commitment and performance.

Related Party Transactions

• The equity awards granted to Gregory Paul Winter, a Director of Bicycle Therapeutics PLC, constitute a related party transaction as it involves compensation to a member of the company's management.

Stakeholder Impact

• Shareholders: The issuance of new shares upon RSU vesting and option exercise could lead to minor dilution, but also aligns director incentives with shareholder value creation.
• Employees: This filing specifically relates to a director's compensation, but generally, such equity awards are a common component of compensation across various employee levels, impacting morale and retention.

Next Steps

• The RSUs will vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• The stock options will vest in four equal installments on March 15, 2026, June 15, 2026, September 15, 2026, and December 15, 2026.
• The stock options will expire on January 2, 2036.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned equity compensation award to a director. While it aligns management incentives with shareholder interests, it does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. It is an expected event within standard corporate governance and compensation practices.

Keywords

Bicycle Therapeutics, BCYC, Form 4, Insider Transaction, Equity Award, Restricted Share Units, Stock Options, Director Compensation, Gregory Paul Winter, Rule 10b5-1